Literature DB >> 33300579

Comparison of Estimated SARS-CoV-2 Seroprevalence through Commercial Laboratory Residual Sera Testing and a Community Survey.

Kristina L Bajema1, F Scott Dahlgren1, Travis W Lim1, Nicolette Bestul1, Holly M Biggs1, Jacqueline E Tate1, Claudio Owusu1, Christine M Szablewski1,2, Cherie Drenzek2, Jan Drobeniuc1, Vera Semenova1, Han Li1, Peter Browning1, Rita Desai1, Monica Epperson1, Lily T Jia1, Natalie J Thornburg1, Chris Edens1, Alicia M Fry1, Aron J Hall1, Jarad Schiffer1, Fiona P Havers1.   

Abstract

We compared severe acute respiratory syndrome-related coronavirus-2 seroprevalence estimated from commercial laboratory residual sera and a community household survey in metropolitan Atlanta during April-May 2020 and found these two estimates to be similar (4.94% versus 3.18%). Compared with more representative surveys, commercial sera can provide an approximate measure of seroprevalence. Published by Oxford University Press for the Infectious Diseases Society of America 2020.

Entities:  

Keywords:  Convenience sampling; Coronavirus disease 2019 (COVID-19); Seroprevalence; Severe acute respiratory syndrome–related coronavirus-2 (SARS-CoV-2)

Year:  2020        PMID： 33300579      PMCID： PMC7799302          DOI： 10.1093/cid/ciaa1804

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  5 in total

1.  Assessment of SARS-CoV-2 Seroprevalence by Community Survey and Residual Specimens, Denver, Colorado, July-August 2020.

Authors:  Kiersten J Kugeler; Laura J Podewils; Nisha B Alden; Tori L Burket; Breanna Kawasaki; Brad J Biggerstaff; Holly M Biggs; Rachael Zacks; Monique A Foster; Travis Lim; Emily McDonald; Jacqueline E Tate; Rachel K Herlihy; Jan Drobeniuc; Margaret M Cortese
Journal:  Public Health Rep       Date:  2021-11-09       Impact factor: 2.792

2.  Risk Factors Associated With SARS-CoV-2 Seropositivity Among US Health Care Personnel.

Authors:  Jesse T Jacob; Julia M Baker; Scott K Fridkin; Benjamin A Lopman; James P Steinberg; Robert H Christenson; Brent King; Surbhi Leekha; Lyndsay M O'Hara; Peter Rock; Gregory M Schrank; Mary K Hayden; Bala Hota; Michael Y Lin; Brian D Stein; Patrizio Caturegli; Aaron M Milstone; Clare Rock; Annie Voskertchian; Sujan C Reddy; Anthony D Harris
Journal:  JAMA Netw Open       Date:  2021-03-01

3.  A phenomenological estimate of the true scale of CoViD-19 from primary data.

Authors:  Luigi Palatella; Fabio Vanni; David Lambert
Journal:  Chaos Solitons Fractals       Date:  2021-03-14       Impact factor: 5.944

4.  Impact of dexamethasone on the incidence of ventilator-associated pneumonia and blood stream infections in COVID-19 patients requiring invasive mechanical ventilation: a multicenter retrospective study.

Authors:  Ines Gragueb-Chatti; Alexandre Lopez; Dany Hamidi; Christophe Guervilly; Anderson Loundou; Florence Daviet; Nadim Cassir; Laurent Papazian; Jean-Marie Forel; Marc Leone; Jean Dellamonica; Sami Hraiech
Journal:  Ann Intensive Care       Date:  2021-05-31       Impact factor: 6.925

5.  Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Reported Coronavirus Disease 2019 Cases in US Children, August 2020-May 2021.

Authors:  Alexia Couture; B Casey Lyons; Megha L Mehrotra; Lynn Sosa; Ngozi Ezike; Farah S Ahmed; Catherine M Brown; Stephanie Yendell; Ihsan A Azzam; Božena J Katić; Anna Cope; Kristen Dickerson; Jolianne Stone; L Brannon Traxler; John R Dunn; Lora B Davis; Carrie Reed; Kristie E N Clarke; Brendan Flannery; Myrna D Charles
Journal:  Open Forum Infect Dis       Date:  2022-01-30       Impact factor: 3.835
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.